Rivaroxaban in stroke prevention in patients with non-valvular atrial fibrillation: what facts are important for the clinician?

The article discusses the results of randomized controlled trials and some observational studies that define the current understanding of the role of rivaroxaban in the prevention of cardioembolic complications in patients with atrial fibrillation (AF). According to the results of the randomized controlled trial ROCKET AF, in patients with non-valvular AF, rivaroxaban is at least as effective as warfarin. At the same time, while the rates of major and clinically significant non-major bleeding were comparable, fatal bleeding and bleeding in critical organs (including intracranial bleeding) were less frequent in the rivaroxaban group, whereas clinically relevant gastrointestinal bleeding occurred more often. Overall, the rate of major gastrointestinal bleeding increased by 10 cases per 1,000 treated patients per year in the rivaroxaban group, and its occurrence did not lead to the need for large-volume blood transfusions or an increased risk of death. Similar clinical effects can be expected in various patient categories, including those with impaired kidney function (down to a creatinine clearance of 15 mL/min) and elderly patients. According to accumulated evidence, rivaroxaban reduces the risk of coronary thrombosis after coronary stenting and should be combined with one antiplatelet agent (mainly clopidogrel) in this case. According to the results of the X-VERT study, rivaroxaban appears to be an effective and safe alternative to vitamin K antagonists during cardioversion and may allow for rapid cardioversion in hemodynamically stable patients with paroxysmal non-valvular AF. Due to the lack of an available laboratory monitoring method and significant variations in drug concentration in the blood among those receiving rivaroxaban, studies on bioequivalence with determination of anti-Xa activity in the blood are particularly important for its generics. Data on the similar composition of tablets, comparable dissolution kinetics and bioequivalence are available, in particular, from the Russian generic rivaroxaban Zinacoren.

1. Joglar JA, Chung MK, Armbruster AL, et al.; Рeer Review Committee Members. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(1):e1-e156. DOI:10.1161/CIR.0000000000001193. Erratum in: Circulation. 2024;149(1):e167. DOI:10.1161/CIR.0000000000001207. Erratum in: Circulation. 2024;149(9):e936. DOI:10.1161/CIR.0000000000001218. Erratum in: Circulation. 2024;149(24):e1413. DOI:10.1161/CIR.0000000000001263.

2. Van Gelder IC, Rienstra M, Bunting KV, et al.; ESC Scientific Document Group. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314-14. DOI:10.1093/eurheartj/ehae176.

3. Arakelyan MG, Bockeria LA, Vasilieva EYu, et al. 2020 Clinical guidelines for Atrial fibrillation and atrial flutter. Russian Journal of Cardiology 2021;26(7):4594. (In Russ.) DOI:10.15829/1560-4071-2021-4594.

4. Granger CB, Alexander JH, McMurray JJ, et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92. DOI:10.1056/NEJMoa1107039.

5. Giugliano RP, Ruff CT, Braunwald E, et al.; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093-104. DOI:10.1056/NEJMoa1310907.

6. Connolly SJ, Ezekowitz MD, Yusuf S, et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-351. DOI:10.1056/NEJMoa0905561.

7. Patel MR, Mahaffey KW, Garg J, et al.; ROCKET-AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91. DOI:10.1056/NEJMoa1009638.

8. Steffel J, Collins R, Antz M, et al. External reviewers. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021;23(10):1612-76. DOI:10.1093/europace/euab065.

9. Almalbis CA, Md Redzuan A, Andrada CP, et al. Peak and trough concentrations of apixaban and rivaroxaban in adult patients: a systematic review and meta-analysis. J Thromb Haemost 2025;23(4):1289-314. DOI:10.1016/j.jtha.2024.12.032.

10. Patel MR, Hellkamp AS, Lokhnygina Y, et al. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). J Am Coll Cardiol. 2013;61(6):651-8. DOI:10.1016/j.jacc.2012.09.057.

11. Sherwood MW, Nessel CC, Hellkamp AS, et al. Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF Trial. J Am Coll Cardiol. 2015;66(21):2271-81. DOI:10.1016/j.jacc.2015.09.024.

12. Mahaffey KW, Stevens SR, White HD, et al.; ROCKET AF Investigators. Ischemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. Eur Heart J. 2014;35(4):233-41. DOI:10.1093/eurheartj/eht428.

13. Hankey GJ, Patel MR, Stevens SR, et al.; ROCKET AF Steering Committee Investigators. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol. 2012;11(4):315-22. DOI:10.1016/S1474-4422(12)70042-X.

14. Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32(19):2387-94. DOI:10.1093/eurheartj/ehr342.

15. Fordyce CB, Hellkamp AS, Lokhnygina Y, et al.; ROCKET AF Steering Committee and Investigators. On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF. Circulation. 2016;134(1):37-47. DOI:10.1161/CIRCULATIONAHA.116.021890. Erratum in: Circulation. 2016;134(8):e114. DOI:10.1161/CIR.0000000000000451. Erratum in: Circulation. 2020;141(8):e98. DOI:10.1161/CIR.0000000000000763.

16. Chashkina M, Andreev DA, Kozlovskaya NL, et al. Safety and efficacy of rivaroxaban compared to warfarin in patients with atrial fibrillation and advanced stages of chronic kidney disease [abstract]. Eur Heart J. 2020;41(Suppl 2):ehaa946.3323. DOI:10.1093/ehjci/ehaa946.3323.

17. Halperin JL, Hankey GJ, Wojdyla DM, et al.; ROCKET AF Steering Committee and Investigators. Efficacy and Safety of Rivaroxaban Compared with Warfarin among Elderly Patients with Nonvalvular Atrial Fibrillation in the ROCKET AF Trial. Circulation. 2014;130(2):138-46. DOI:10.1161/CIRCULATIONAHA.113.005008. Erratum in: Circulation. 2018;138(25):e783. DOI:10.1161/CIR.0000000000000637.

18. Hanon O, Vidal JS, Pisica-Donose G, et al.; SAFIR study group. Bleeding risk with rivaroxaban compared with vitamin K antagonists in patients aged 80 years or older with atrial fibrillation. Heart. 2021;107(17):1376-82. DOI:10.1136/heartjnl-2020-317923.

19. Gibson CM, Mehran R, Bode C, et al. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Am Heart J. 2015;169(4):472-8. DOI:10.1016/j.ahj.2014.12.006.

20. Byrne RA, Rossello X, Coughlan JJ, et al.; ESC Scientific Document Group. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720-826. DOI:10.1093/eurheartj/ehad191.

21. Cappato R, Ezekowitz MD, Klein AL, et al.; X-VeRT Investigators. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014;35(47):3346-55. DOI:10.1093/eurheartj/ehu367.

22. Vertkin AL, Knorring GYu, Rodyukova IS, et al. Equivalence study of the Generic Rivaroxaban Zinacoren in vitro and in vivo. Effective pharmacotherapy 2024;20(51):8-18. (In Russ.). DOI:10.33978/2307-3586-2024-20-51-8-18.

23. Suvorova AV, Losenkova PA, Medvedev YuV, et al. Application of in vitro studies to predict the pharmacokinetics of rivaroxaban tablets. Drug development & registration. 2024;13(3):186-98. (In Russ.) DOI:10.33380/2305-2066-2024-13-3-1908.